Assyro AI

Orange Book product · Brand (NDA)

INVELTYS

LOTEPREDNOL ETABONATE

Brand (NDA)NDA 210565RX ALCON LABS INC

At a glance

Aug 22, 2018

Approved

Brand (NDA)

Application

Not listed

TE code

14

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 22, 2018

    7 yr 11 mo ago

  2. Today

  3. Patent 10058511 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  4. Patent 10646437 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  5. Patent 10688045 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  6. Patent 10864219 expires

    Listed method-of-use patent (U-3011) expiration.

    May 03, 2033

    in 7 yr

  7. Patent 11219597 expires

    Listed method-of-use patent (U-3278) expiration.

    May 03, 2033

    in 7 yr

  8. Patent 11219597 expires

    Listed method-of-use patent (U-3279) expiration.

    May 03, 2033

    in 7 yr

  9. Patent 11642317 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  10. Patent 11872318 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  11. Patent 12115246 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  12. Patent 9056057 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  13. Patent 9393213 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

  14. Patent 9532955 expires

    Listed method-of-use patent (U-2491) expiration.

    May 03, 2033

    in 7 yr

  15. Patent 9737491 expires

    Listed method-of-use patent (U-2492) expiration.

    May 03, 2033

    in 7 yr

  16. Patent 9827191 expires

    Listed drug product patent expiration.

    May 03, 2033

    in 7 yr

Pharmaceutical detail

Active ingredient

LOTEPREDNOL ETABONATE

Strength

1%

Dosage form

SUSPENSION/DROPS

Route

OPHTHALMIC

TE code

Not listed

Application

NDA 210565

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (14)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10058511May 03, 2033in 7 yr
ProductU-2492
10646437May 03, 2033in 7 yr
Product
10688045May 03, 2033in 7 yr
Product
10864219May 03, 2033in 7 yr
U-3011
11219597May 03, 2033in 7 yr
U-3278
11219597May 03, 2033in 7 yr
U-3279
11642317May 03, 2033in 7 yr
Product
11872318May 03, 2033in 7 yr
Product
12115246May 03, 2033in 7 yr
ProductU-4025
9056057May 03, 2033in 7 yr
ProductU-2491
9393213May 03, 2033in 7 yr
Product
9532955May 03, 2033in 7 yr
U-2491
9737491May 03, 2033in 7 yr
U-2492
9827191May 03, 2033in 7 yr
ProductU-2493
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.